Physician profile
Tabitha D Culver
NPI 1508090424
$2,764.42
in general payments reported to CMS, 2019-2025
30 companies · $137 in 2025
The $137 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,174 · 2020: $153 · 2021: $111 · 2022: $286 · 2023: $495 · 2024: $409 · 2025: $137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $496.63 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $294.30 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $275.17 | 2019-2024 | |
| Novo Nordisk INC | $256.66 | 2019-2025 | Ozempic, Wegovy |
| Lilly USA, LLC | $162.20 | 2019-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $149.53 | 2019-2023 | Farxiga |
| Amgen INC. | $142.32 | 2019-2025 | Repatha, Otezla, Repatha |
| Xeris Pharmaceuticals, INC. | $138.24 | 2022-2023 | Gvoke Hypopen |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.35 | 2019-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $104.63 | 2023-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $94.56 | 2019-2025 | Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.10 | 2019-2023 | Ofev |
| Biohaven Pharmaceuticals, INC. | $78.62 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $72.16 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.29 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $33.64 | 2024-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $31.74 | 2020-2023 | Myrbetriq |
| Boston Scientific Corporation | $19.66 | 2023 | Watchman Access System |
| Abbott Laboratories | $18.31 | 2024 | Freestyle Libre 3 |
| Phathom Pharmaceuticals, INC. | $18.22 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $14.17 | 2022 | |
| Amarin Pharma, INC. | $13.82 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.82 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $13.38 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $13.22 | 2019 | |
| Nestle Healthcare Nutrition INC. | $12.78 | 2022 | |
| Insulet Corporation | $12.77 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.54 | 2022 | |
| Inogen, INC. | $12.12 | 2022 | |
| Allergan, INC. | $11.47 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Culver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.